This article is more than 5 years old. Information may no longer be current.
VIDEO: ‘Transformative’ ASCO abstracts highlight progress with biomarkers, targeted therapies
CHICAGO — The ASCO Annual Meeting featured several “transformative” abstracts, according to Edward S. Kim, MD, chairman of solid tumor oncology at Levine Cancer Institute at Carolinas HealthCare System and a HemOnc Today Editorial Board member.
“It’s really quite cool to say how abstracts over the last decade have evolved,” Kim said. “This year, we’re not talking about phase 3 trials with marginal benefits or cytotoxic chemotherapies that may add a seventh or eighth treatment to a different tumor type. These days, we’re talking about biomarkers and the ways we can obtain [them].”
Kim discusses the importance of biomarkers, targeted therapies and precision medicine.
He also describes the TAPUR study, an ASCO-led clinical trial designed to assess the use of FDA–approved, molecularly targeted cancer therapies in patients with advanced cancers that may have actionable genomic variants.
Read more from ASCO Annual Meeting
View all
Read more about